Research Center for Integrative Medicine in Aging, Aging Research Institute, Tabriz University of Medical Sciences, Golgasht Street, Tabriz, 51666, EA, Iran.
Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Eur J Med Res. 2024 Oct 26;29(1):514. doi: 10.1186/s40001-024-02108-8.
Leukemia remains a major therapeutic challenge in clinical oncology. Despite significant advancements in treatment modalities, leukemia remains a significant cause of morbidity and mortality worldwide, as the current conventional therapies are accompanied by life-limiting adverse effects and a high risk of disease relapse. Histone deacetylase inhibitors have emerged as a promising group of antineoplastic agents due to their ability to modulate gene expression epigenetically. In this review, we explore these agents, their mechanisms of action, pharmacokinetics, safety and clinical efficacy, monotherapy and combination therapy strategies, and clinical challenges associated with histone deacetylase inhibitors in leukemia treatment, along with the latest evidence and ongoing studies in the field. In addition, we discuss future directions to optimize the therapeutic potential of these agents.
白血病仍然是临床肿瘤学的主要治疗挑战。尽管在治疗方式上取得了重大进展，但白血病仍然是全球发病率和死亡率的主要原因，因为目前的常规治疗方法伴随着危及生命的不良反应和疾病复发的高风险。组蛋白去乙酰化酶抑制剂因其能够在表观遗传学上调节基因表达而成为一类很有前途的抗肿瘤药物。在这篇综述中，我们探讨了这些药物的作用机制、药代动力学、安全性和临床疗效、单药治疗和联合治疗策略以及与白血病治疗中组蛋白去乙酰化酶抑制剂相关的临床挑战，以及该领域的最新证据和正在进行的研究。此外，我们还讨论了优化这些药物治疗潜力的未来方向。
